ライフサイエンスコーパス: sulfamethoxazole

1 rmetoprim-sulfadimethoxine, and trimethoprim-sulfamethoxazole).

2 n, clindamycin, gentamicin, and trimethoprim-sulfamethoxazole.

3 d dicloxacillin, but not abacavir or nitroso sulfamethoxazole.

4 amycin, gentamicin sulfate, and trimethoprim-sulfamethoxazole.

5 ine, tigecycline, rifampin, and trimethoprim/sulfamethoxazole.

6 MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole.

7 r PcP with a combination of trimethoprim and sulfamethoxazole.

8 except for chloramphenicol and trimethoprim-sulfamethoxazole.

9 sting 567 staphylococci against trimethoprim-sulfamethoxazole.

10 eceived antibiotic therapy with trimethoprim-sulfamethoxazole.

11 ent course of ciprofloxacin and trimethoprim-sulfamethoxazole.

12 espite anti-Pc prophylaxis with trimethoprim-sulfamethoxazole.

13 erythromycin, tetracycline, and trimethoprim-sulfamethoxazole.

14 infants also received high-dose trimethoprim-sulfamethoxazole.

15 oroquinolones, penicillins, and trimethoprim-sulfamethoxazole.

16 cin, rifampin, minocycline, and trimethoprim-sulfamethoxazole.

17 profloxacin, gentamicin, and/or trimethoprim-sulfamethoxazole.

18 nd 57 (82.6%) were resistant to trimethoprim-sulfamethoxazole.

19 or macrolide antibiotic, or for trimethoprim-sulfamethoxazole.

20 hfr, which confer resistance to trimethoprim-sulfamethoxazole.

21 and only 7% were susceptible to trimethoprim-sulfamethoxazole.

22 h ampicillin, trimethoprim, and trimethoprim-sulfamethoxazole.

23 coli strains with resistance to trimethoprim-sulfamethoxazole.

24 in all 19 patients treated with trimethoprim-sulfamethoxazole.

25 oramphenicol, erythromycin, and trimethoprim-sulfamethoxazole.

26 or patients who cannot tolerate trimethoprim-sulfamethoxazole.

27 erythromycin, clindamycin, and trimethoprim-sulfamethoxazole.

28 rpreted based on human data for trimethoprim-sulfamethoxazole.

29 ulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole.

30 to beta-lactam antibiotics and trimethoprim-sulfamethoxazole.

31 specially clarithromycin, ciprofloxacin, and sulfamethoxazole.

32 receipt of ciprofloxacin and/or trimethoprim-sulfamethoxazole.

33 concern were performed with bisphenol A and sulfamethoxazole.

34 7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole.

35 , 0.5%), and mixed species with trimethoprim-sulfamethoxazole (1 of 366, 0.3%).

36 ate resistance was detected for trimethoprim-sulfamethoxazole (10 strains) and clindamycin (3 strains

37 ndomly assigned to receive oral trimethoprim-sulfamethoxazole (160 mg or 800 mg) or ciprofloxacin (50

38 Trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days), ni

39 = 128 included in analysis) vs trimethoprim-sulfamethoxazole, 160/800 mg twice per day for 14 days (

40 ser extent, to kanamycin (19%), trimethoprim-sulfamethoxazole (17%), and gentamicin (11%).

41 as more frequently resistant to trimethoprim-sulfamethoxazole (18%) than to ciprofloxacin (0%; P<.001

42 <0.1-1.4 days), bezafibrate (<0.1-4.8 days), sulfamethoxazole (2-33 days), naproxen (6-19 days), carb

43 as that of trimethoprim (10 microgram/mL) + sulfamethoxazole (250 microgram/mL), a standard clinical

44 me antibiotics in drinking waters, including sulfamethoxazole (3.0-3.4 ng/L), macrolides (1.4-4.9 ng/

45 xin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice daily, for 7 days

46 prescribed, only ofloxacin (1 ng.L(-1)) and sulfamethoxazole (4 ng.L(-1)) persisted in the river.

47 olates that were susceptible to trimethoprim-sulfamethoxazole (4 percent, P<0.001).

48 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to nalidixic aci

49 isolates displayed resistance most often to sulfamethoxazole (57%), streptomycin (56%), tetracycline

50 (92%), and sulfamethoxazole or trimethoprim-sulfamethoxazole (70%).

51 ations and overall was best for trimethoprim-sulfamethoxazole (75% for one isolate and 100% for all o

52 to penicillin, macrolides, and trimethoprim-sulfamethoxazole, 8 had other resistance patterns, and 3

53 3.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (80%); however, categorical concordance

54 ully treated in all cases using trimethoprim-sulfamethoxazole (800 mg/160 mg) twice daily for 45 days

55 ent on-scale MICs occurred with trimethoprim-sulfamethoxazole (89.7%).

56 amycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.

57 tewater borne MPs diclofenac, carbamazepine, sulfamethoxazole, acesulfame, sucralose, benzotriazole,

58 in the IAST-EBC successfully modeled MIB and sulfamethoxazole adsorption by three different PACs in t

59 ting a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction assessment and re

60 Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions documented eithe

61 ared with standard prophylaxis (trimethoprim-sulfamethoxazole alone).

62 ine synthesis with the folic acid antagonist sulfamethoxazole also inhibited spreading.

63 the prevalence of resistance to trimethoprim-sulfamethoxazole, ampicillin, and cephalothin increased

64 d high MICs of >4/76 mug/ml for trimethoprim-sulfamethoxazole, an antibiotic commonly used to treat u

65 bramycin; 96% were resistant to trimethoprim-sulfamethoxazole and 41% to ciprofloxacin hydrochloride.

66 cin among S. pneumoniae and for trimethoprim/sulfamethoxazole and azithromycin among H. influenzae.

67 e predicted no-effect levels for diclofenac, sulfamethoxazole and carbamazepine, respectively.

68 recalcitrant contaminants such as sucralose, sulfamethoxazole and carbamazepine, which are typical wa

69 all strains were susceptible to trimethoprim-sulfamethoxazole and ciprofloxacin.

70 for all isolates), followed by trimethoprim-sulfamethoxazole and ciprofloxacin.

71 al human epidermal keratinocytes metabolized sulfamethoxazole and dapsone to N-4-hydroxylamine and N-

72 tigation of metabolism-dependent toxicity of sulfamethoxazole and dapsone, and subsequent incubation

73 n of delayed-type hypersensitivity caused by sulfamethoxazole and dapsone.

74 With trimethoprim-sulfamethoxazole and fluoroquinolones, the drug-bug mism

75 enem, gentamicin, amikacin, and trimethoprim-sulfamethoxazole and had reduced susceptibilities to cef

76 etch of the Simeto River, whereas sucralose, sulfamethoxazole and ibuprofen have always been well cor

77 Trimethoprim-sulfamethoxazole and macrolide use were not significantl

78 0%) and 6 of 47 (12.80%) in the trimethoprim-sulfamethoxazole and placebo groups, respectively (P = .

79 y treatment with the antibiotic trimethoprim-sulfamethoxazole and possibly by coinfection with P. aer

80 ior receipt of ciprofloxacin or trimethoprim-sulfamethoxazole and presence of a gastrostomy tube were

81 tenolol, metoprolol, and trimethoprim, while sulfamethoxazole and propranolol were attenuated mainly

82 te constants of two sulfonamide antibiotics (sulfamethoxazole and sulfadiazine) in the presence of un

83 rpretation of in vitro MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and the lack of qu

84 o MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and the lack of quality controls for No

85 Additional prophylaxis included trimethoprim-sulfamethoxazole and valganciclovir.

86 to ampicillin, gentamicin, and trimethoprim-sulfamethoxazole and with susceptibility to fluoroquinol

87 UMCR1 was only resistant to sulfamethoxazole and, like other S. aureus isolates, pol

88 found to have resistant MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole.

89 a single breakpoint for testing trimethoprim-sulfamethoxazole and/or trimethoprim-sulfadiazine with S

90 lfamethoxazole beta-D-glucuronide, 4-nitroso sulfamethoxazole, and 4-nitro sulfamethoxazole were irra

91 es, 100 percent to rifampin and trimethoprim-sulfamethoxazole, and 92 percent to tetracycline.

92 trated on the pharmaceuticals acetaminophen, sulfamethoxazole, and carbamazepine and on the pharmaceu

93 en who received bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy

94 h HIV receiving bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy

95 ofur, erythromycin, tilmicosin, trimethoprim-sulfamethoxazole, and florfenicol, with some minor varia

96 s but susceptible to aztreonam, trimethoprim-sulfamethoxazole, and fluoroquinolones.

97 isolates were susceptible to ciprofloxacin, sulfamethoxazole, and linezolid and susceptible or inter

98 herapy consisted of tacrolimus, trimethoprim/sulfamethoxazole, and prednisone (the latter two were di

99 lly susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin, but inducible macrolide-

100 ptible in vitro to clindamycin, trimethoprim-sulfamethoxazole, and rifampin.

101 es, macrolides, quinolones, trimethoprim and sulfamethoxazole, and rifampin.

102 emfibrozil, ibuprofen, ketoprofen, naproxen, sulfamethoxazole, and sildenafil).

103 o ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline (the AmCmStSuTe pheno

104 ance to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycline (the AmKmStSuTe pheno

105 ance to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycline and to ampicillin, ch

106 inopenicillin, fluoroquinolone, trimethoprim/sulfamethoxazole, and tetracycline usage on resistance o

107 o ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline, respectively.

108 o ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline.

109 acin, clarithromycin, doxycycline, imipenem, sulfamethoxazole, and tobramycin (M. chelonae only) in f

110 llin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin.

111 cillin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin.

112 penicillins, tetracycline, and trimethoprim-sulfamethoxazole are good treatment options.

113 th S. equi This study indicates trimethoprim-sulfamethoxazole as an acceptable surrogate for trimetho

114 fornia cohort were resistant to trimethoprim-sulfamethoxazole as well as other antibiotics.

115 s with sporadic mutations and a patient with sulfamethoxazole-associated LQTS who carried a single-nu

116 SNP were normal at baseline but inhibited by sulfamethoxazole at therapeutic levels that did not affe

117 epartments to determine whether trimethoprim-sulfamethoxazole (at doses of 320 mg and 1600 mg, respec

118 All investigated metabolites, except sulfamethoxazole beta-D-glucuronide were found to be mor

119 SMX, N-acetyl sulfamethoxazole, sulfamethoxazole beta-D-glucuronide, 4-nitroso sulfameth

120 may enhance antibiotic removal, as shown for sulfamethoxazole; (c) not accounting for fractions sorbe

121 for resistance to erythromycin, trimethoprim-sulfamethoxazole, chloramphenicol, and rifampin by agar

122 Trimethoprim-sulfamethoxazole, ciprofloxacin, and piperacillin-tazoba

123 lowing agents: chloramphenicol, trimethoprim-sulfamethoxazole, ciprofloxacin, and rifampin.

124 d removal efficiencies of three antibiotics (sulfamethoxazole, ciprofloxacin, tetracycline) in pilot-

125 ciprofloxacin, gentamicin, trimethoprim and sulfamethoxazole, clarithromycin, and azithromycin.

126 ycin followed by 1 week of oral trimethoprim-sulfamethoxazole combination therapy.

127 tis, the use of cephalexin plus trimethoprim-sulfamethoxazole compared to cephalexin alone did not re

128 sumed bacterial infections with trimethoprim/sulfamethoxazole (cotrimoxazole) was assessed to see if

129 ntiretroviral therapy or use of trimethoprim-sulfamethoxazole did not impact the risk of MRSA carriag

130 fected cells with retinoic acid and dimethyl sulfamethoxazole enhanced their microbicidal effects.

131 lus treatment with rifampin and trimethoprim-sulfamethoxazole eradicated the infection.

132 lids biochar, and coal-derived PAC to remove sulfamethoxazole from wastewater.

133 isolates that were resistant to trimethoprim-sulfamethoxazole from women with community-acquired urin

134 11 percent to 16 percent), and trimethoprim-sulfamethoxazole (from 25 percent to 29 percent).

135 erence favoring cephalexin plus trimethoprim-sulfamethoxazole, further research may be needed.

136 luding ampicillin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin, and ciprofloxacin) reporte

137 -10, and mediated resistance to trimethoprim-sulfamethoxazole, gentamicin, and tobramycin; all 20 iso

138 ofloxacin, rifampin, vancomycin, ampicillin, sulfamethoxazole, gentamicin, or metronidazole).

139 it for 428 children (214 in the trimethoprim-sulfamethoxazole group and 214 in the placebo group).

140 524 participants (0.4%) in the trimethoprim-sulfamethoxazole group and in 2 of 533 participants (0.4

141 Weight gain in the trimethoprim-sulfamethoxazole group and the placebo group was similar

142 630 participants (80.5%) in the trimethoprim-sulfamethoxazole group versus 454 of 617 participants (7

143 524 participants (92.9%) in the trimethoprim-sulfamethoxazole group versus 457 of 533 participants (8

144 icipants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 165 (85.5%) of 193 in the ceph

145 icipants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 171 (69.0%) of 248 in the ceph

146 in 1 participant (0.2%) in the trimethoprim-sulfamethoxazole group.

147 s were resistant to the cytotoxic effects of sulfamethoxazole hydroxylamine but not dapsone hydroxyla

148 Covalent adduct formation by sulfamethoxazole hydroxylamine was detected in normal hu

149 Major protein targets of sulfamethoxazole hydroxylamine were observed in the regi

150 ocytes became susceptible to the toxicity of sulfamethoxazole hydroxylamine.

151 zole in 21.7% of strains and to trimethoprim-sulfamethoxazole in 21.0% resulted from polymorphisms of

152 ctrometry, and it was demonstrated to screen sulfamethoxazole in a complex matrix such as seawater, w

153 d-pyridoxine (coformulated with trimethoprim-sulfamethoxazole in a single fixed-dose combination tabl

154 cin, doxycycline, imipenem, and trimethoprim-sulfamethoxazole in each of four laboratories.

155 re than 20% for ampicillin, cephalothin, and sulfamethoxazole in each year studied.

156 Resistance to trimethoprim-sulfamethoxazole in Iran is low and this drug should be

157 Sulfamethoxazole in particular had a stimulatory effect

158 rmation rates increased for trimethoprim and sulfamethoxazole in the dark, when microbial respiration

159 or atenolol, carbamazepine, propranolol, and sulfamethoxazole in wetland water under representative c

160 While trimethoprim-sulfamethoxazole is considered first-line therapy for Pn

161 A 1-week course of trimethoprim-sulfamethoxazole is effective in HIV-infected patients w

162 of Pneumocystis pneumonia with trimethoprim/sulfamethoxazole is effective in reducing this risk.

163 Trimethoprim-sulfamethoxazole is the preferred drug regimen for both

164 exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is a determinant

165 we demonstrated that (a) the elimination of sulfamethoxazole may be significantly underestimated whe

166 ion, >/=1 microg/mL) and 19% to trimethoprim/sulfamethoxazole (minimal inhibitory concentration, >/=4

167 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]) was limited

168 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant S. Typhi [MDRST]);

169 mpicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant Salmonella Typhi [

170 or >/=40% (beta-lactams), >50% (trimethoprim-sulfamethoxazole , multidrug), or >70% (ciprofloxacin, g

171 iate antimicrobial therapy with trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfomycin is indic

172 CI), 0.60-0.97; P =.03; risk of trimethoprim-sulfamethoxazole nonsusceptibility was also lower in the

173 Trimethoprim-sulfamethoxazole or methotrexate may be valuable in sele

174 Trimethoprim-sulfamethoxazole or placebo taken orally, once daily, fo

175 ionally, each was randomized to trimethoprim-sulfamethoxazole or placebo.

176 0%), rifabutin (100%), ethambutol (92%), and sulfamethoxazole or trimethoprim-sulfamethoxazole (70%).

177 nd less frequently resistant to trimethoprim-sulfamethoxazole (OR = 0.38; 95% CI = 0.18 to 0.80; P =

178 reated with other beta-lactams, trimethoprim-sulfamethoxazole, or vancomycin.

179 llin-clavulanic acid (P = .03), trimethoprim-sulfamethoxazole (P = .01), and ciprofloxacin (P = .03)

180 cephalothin, trimethoprim, and trimethoprim-sulfamethoxazole (P<.001).

181 most common antimicrobials were trimethoprim-sulfamethoxazole, penicillin, and amoxicillin (22%, 8/37

182 , which consisted of continuous trimethoprim-sulfamethoxazole plus at least 12 weeks of isoniazid-pyr

183 Besides biotransformation (sulfamethoxazole), poor membrane permeability (cimetidin

184 erm treatment with combined trimethoprim and sulfamethoxazole prevented recurrent disease in patients

185 Trimethoprim-sulfamethoxazole promotes the excision of all, and cipro

186 s associated with no treatment, trimethoprim-sulfamethoxazole prophylaxis alone, antiretroviral thera

187 ical criteria, as compared with trimethoprim-sulfamethoxazole prophylaxis alone.

188 A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretroviral therapy,

189 Women received daily trimethoprim-sulfamethoxazole prophylaxis and insecticide-treated bed

190 was controlled after systematic trimethoprim-sulfamethoxazole prophylaxis in exposed patients.

191 n, we evaluated the efficacy of trimethoprim-sulfamethoxazole prophylaxis in preventing recurrences (

192 Trimethoprim/sulfamethoxazole prophylaxis was associated with a reduc

193 her cases were identified after trimethoprim-sulfamethoxazole prophylaxis was introduced in the entir

194 from a large clinical trial of trimethoprim-sulfamethoxazole prophylaxis, there was no evidence that

195 fective as those that also used trimethoprim-sulfamethoxazole prophylaxis.

196 Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered before antire

197 mpin, parenteral gentamicin, or trimethoprim-sulfamethoxazole provide the best therapeutic choices to

198 icantly more patients underwent trimethoprim-sulfamethoxazole rechallenge after protocol implementati

199 ction of a standard approach to trimethoprim-sulfamethoxazole rechallenge in the context of both prio

200 men and 83% (92 of 111) for the trimethoprim-sulfamethoxazole regimen (95% CI, 0.06-0.22; P = .002).

201 men and 89% (90 of 101) for the trimethoprim-sulfamethoxazole regimen (95% confidence interval [CI] f

202 inical cure rates than a 14-day trimethoprim-sulfamethoxazole regimen, especially in patients infecte

203 ving secondary prophylaxis with trimethoprim-sulfamethoxazole remained disease-free, and 15 of 16 pat

204 i pneumonia; the combination of trimethoprim-sulfamethoxazole remains the first-line agent for both t

205 p A), in 28 of 55 isolates with trimethoprim-sulfamethoxazole resistance (51 percent) and in 2 of 50

206 el significantly predicted both trimethoprim-sulfamethoxazole resistance (prevalence ratio, 2.7 [95%

207 etracycline resistance), and an unidentified sulfamethoxazole resistance allele.

208 It also carried the sul1 gene for sulfamethoxazole resistance and a 1-kb class I integron

209 ized significant contributor to trimethoprim-sulfamethoxazole resistance in the United States.

210 ycin resistance (ICR) (n = 30), trimethoprim-sulfamethoxazole-resistant MRSA (n = 10), vancomycin-res

211 ially in patients infected with trimethoprim-sulfamethoxazole-resistant strains.

212 re resistant to clindamycin and trimethoprim/sulfamethoxazole, respectively.

213 effect to increase and decrease with MIB and sulfamethoxazole, respectively.

214 Cefprozil, cefaclor, and trimethoprim-sulfamethoxazole results differed the most, while result

215 ntimicrobial agents tested; the trimethoprim-sulfamethoxazole results were lower with Etest, particul

216 Trimethoprim-sulfamethoxazole retains clinical efficacy, but resistan

217 resistance to trimethoprim and trimethoprim-sulfamethoxazole rose from more than 9% in 1992 to more

218 that P. carinii is developing resistance to sulfamethoxazole (SMX) and dapsone.

219 amethoxydiazine (SMD), sulfamethazine (SMT), sulfamethoxazole (SMX) and sulfadiazine (SDZ) in importe

220 ), ciprofloxacin (CIP), roxarsone (ROX), and sulfamethoxazole (SMX) antibiotics in agriculturally rel

221 Treatment with sulfamethoxazole (SMX) can lead to hypersensitivity reac

222 t increased susceptibility to the antibiotic sulfamethoxazole (SMX) compared with channels formed wit

223 ted (AC) or unacclimated (UAC) to historical sulfamethoxazole (SMX) contamination, and a laboratory-g

224 Carbon isotope fractionation of sulfamethoxazole (SMX) during biodegradation by Microbac

225 Sulfamethoxazole (SMX), a widely used antibiotic, has be

226 This concept has been applied to sulfamethoxazole (SMX), one of the many antibiotics used

227 lysis of human metabolites of the antibiotic sulfamethoxazole (SMX).

228 have used a T cell-priming assay and nitroso sulfamethoxazole (SMX-NO) as a model Ag to investigate t

229 se and solution of three sulphonamides (SAs; sulfamethoxazole, SMX; sulfamethazine, SMZ; and sulfadim

230 SMX, N-acetyl sulfamethoxazole, sulfamethoxazole beta-D-glucuronide, 4

231 th KRV and a combination of trimethoprim and sulfamethoxazole (Sulfatrim) beginning on the day of inf

232 ociated infections resistant to trimethoprim-sulfamethoxazole, sulfisoxazole, streptomycin, and furaz

233 rim-sulfamethoxazole (TMP-SMX), 355 (32%) to sulfamethoxazole-sulfisoxazole, 312 (28%) to tetracyclin

234 o ampicillin, chloramphenicol, streptomycin, sulfamethoxazole-sulfisoxazole, and tetracycline, includ

235 of 120) were also resistant to trimethoprim-sulfamethoxazole (SXT) (97 of 120 isolates, or 80%), and

236 Ten days of trimethoprim-sulfamethoxazole (SXT) therapy reduces urinary recurrenc

237 Overall ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT), and cefazolin (CFZ) susceptibili

238 been described as resistant to trimethoprim-sulfamethoxazole (SXT), but the test medium may affect t

239 nts were randomized to Group 1 (trimethoprim/sulfamethoxazole tablet every 2 days) or Group 2 (identi

240 riasis ceased more rapidly with trimethoprim-sulfamethoxazole than with ciprofloxacin.

241 xpressed resistance only to streptomycin and sulfamethoxazole (the StSu phenotype; 8.3% of serovar Ty

242 However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent parasitemia did

243 Trimethoprim/sulfamethoxazole therapy resulted in a 100% reduction in

244 followed by phosphomycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuroxime (7%).

245 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolones were act

246 Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-treated nets

247 ntibiotic therapy included oral trimethoprim-sulfamethoxazole (TMP-SMX) and rifampin, TMP-SMX alone,

248 Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but

249 o receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days.

250 V protease inhibitors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activity against p

251 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used for Pneumocyst

252 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used in malaria-end

253 s, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

254 xposed (n = 175) and prescribed trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

255 ) to streptomycin, 402 (36%) to trimethoprim-sulfamethoxazole (TMP-SMX), 355 (32%) to sulfamethoxazol

256 es (43%) were nonsusceptible to trimethoprim-sulfamethoxazole (TMP-SMX), and all isolates were clinda

257 rofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin.

258 ssigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for 10 days.

259 en the increasing resistance to trimethoprim-sulfamethoxazole (TMP-SMX), the current drug of choice f

260 Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opportunistic infec

261 ract infections (UTI) caused by trimethoprim-sulfamethoxazole (TMP-SMX)-resistant Escherichia coli is

262 Trimethoprim-sulfamethoxazole (TMP-SMZ) is an alternative treatment f

263 Trimethoprim-sulfamethoxazole (TMP-SMZ) is the most effective Pneumoc

264 lts, and many receive long-term trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic therapy.

265 kely than controls to have used trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis (odds ratio [OR],

266 sms is typically susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), and this therefore represent

267 The efficacy of trimethoprim-sulfamethoxazole (TMP/SMX) in the prevention of toxoplas

268 le antifolates such as Bactrim (trimethoprim-sulfamethoxazole; TMP-SMX) continue to play an important

269 ithout abscess, the addition of trimethoprim-sulfamethoxazole to cephalexin did not improve outcomes

270 Among trimethoprim-sulfamethoxazole-treated patients, drug resistance was a

271 ated patients and in 33% of 187 trimethoprim-sulfamethoxazole-treated patients, respectively (95% CI,

272 gs in which MRSA was prevalent, trimethoprim-sulfamethoxazole treatment resulted in a higher cure rat

273 t to most antibiotics, with the exception of sulfamethoxazole-trimethoprim (SXT).

274 Retrospective single-center study comparing sulfamethoxazole-trimethoprim 800/160 mg (SMZ/TMP) daily

275 e genes and mobile genetic elements, such as sulfamethoxazole-trimethoprim constins and class I integ

276 initial management of chronic diarrhea with sulfamethoxazole-trimethoprim in HIV-1-infected persons

277 nosis of furunculosis was made, and Bactrim (sulfamethoxazole-trimethoprim; AR Scientific, Philadelph

278 13.82), ampicillin (6.02; 95%CI: 3.31-8.73), sulfamethoxazole/ trimethoprim (4.49; 95%CI: 2.42-6.56),

279 %; tobramycin, 90.6%; gentamicin, 80.6%; and sulfamethoxazole/trimethoprim, 59.4%.

280 lowing: vancomycin, 100%; gentamicin, 88.0%; sulfamethoxazole/trimethoprim, 77.5%; levofloxacin, 58.5

281 Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were admini

282 Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were admini

283 romycin, but CA-MRSA was more susceptible to sulfamethoxazole/trimethoprim.

284 oxine-pyrimethamine (SP), daily trimethoprim-sulfamethoxazole (TS), or monthly dihydroartemisinin-pip

285 ve to minocycline, doxycycline, trimethoprim-sulfamethoxazole, vancomycin, teicoplanin, and linezolid

286 isolates that were resistant to trimethoprim-sulfamethoxazole was 63% in the prophylaxis group and 19

287 Trimethoprim-sulfamethoxazole was associated with slightly more gastr

288 Trimethoprim-sulfamethoxazole was superior to placebo with respect to

289 cin, meropenem, tobramycin, and trimethoprim-sulfamethoxazole were comparable for the two methods: th

290 ical center, even though no tetracycline and sulfamethoxazole were consumed, the highest occurrences

291 , tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole were determined for each isolate, as we

292 w form of carbamazepine and two new forms of sulfamethoxazole were discovered; in these cases, single

293 ide, 4-nitroso sulfamethoxazole, and 4-nitro sulfamethoxazole were irradiated under various light sou

294 cale system (t1/2 < 0.5 d), trimethoprim and sulfamethoxazole were transformed more slowly (t1/2 appr

295 persistent antibiotic compounds (ofloxacin, sulfamethoxazole) were found, but they did not correspon

296 veral compounds, including carbamazepine and sulfamethoxazole, were detected throughout the study rea

297 discaviarum were susceptible to trimethoprim-sulfamethoxazole, while 8% of N. farcinica isolates were

298 Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood concentratio

299 ylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapies, including

300 termine whether cephalexin plus trimethoprim-sulfamethoxazole yields a higher clinical cure rate of u